Zentalis Pharmaceuticals, INC Form 4 insider transactions

Director Luke Walker of Zentalis Pharmaceuticals purchased 14,200 shares of common stock at $1.7582 per share on January 31, 2025.

Zentalis Pharmaceuticals CEO Julia Marie Eastland purchased 28,500 shares of common stock at a price of $1.7314 per share on January 31, 2025.

Mark Lackner, Chief Scientific Officer of Zentalis Pharmaceuticals, sold 4,411 shares of common stock on January 2, 2025, to cover tax withholding obligations related to vested restricted stock units.

Zentalis Pharmaceuticals' Chief Medical Officer, Ingmar Bruns, was granted 712,650 stock options on December 2, 2024, which vest over a four-year period.

Zentalis Pharmaceuticals CEO, Julia Marie Eastland, was granted 3,028,800 stock options on December 2, 2024, which will vest over four years.

Director Scott Myers of Zentalis Pharmaceuticals acquired 260,192 shares of common stock through the vesting of restricted stock units.

Vincent Vultaggio, Principal Accounting Officer of Zentalis Pharmaceuticals, sold 1,603 shares of common stock on October 4, 2024, to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Director Jan Skvarka reports acquiring and disposing of Zentalis Pharmaceuticals common stock, including restricted stock units, in a recent SEC filing.

Director Enoch Kariuki reports acquisition of restricted stock units and disposal of common stock.

Director David Michael Johnson acquired 48,429 restricted stock units in Zentalis Pharmaceuticals, Inc. on June 21, 2024.

Cam Gallagher, President and Interim CFO of Zentalis Pharmaceuticals, sold 9,597 shares of common stock on May 31, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Director Luke Walker reports acquiring 72,481 shares of Zentalis Pharmaceuticals common stock on May 24, 2024, through restricted stock units.

Diana Hausman, Chief Medical Officer of Zentalis Pharmaceuticals, sold 3,356 shares of common stock on May 9, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.